

BAB VII

DAFTAR PUSTAKA

1. Radioactive Iodine For Thyroid Malignancies - statpearls - NCBI bookshelf [Internet]. [cited 2022Oct19]. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK580567/>
2. The Global Cancer Observatory. Global Burden of Cancer Study (Globocan) 2020. 2020;19–20. Available from: <https://gco.iarc.fr/today>
3. Olson E, Wintheiser G, Wolfe KM, Droessler J, Silberstein PT. Epidemiology of Thyroid Cancer: A Review of the National Cancer Database, 2000-2013. *Cureus*. 2019;11(2).
4. Wibisana IGNG. Karsinoma Tiroid. In: Kapita Selekta. V. Depok: Media Aesculapius; 2020;763–7.
5. Fard-Esfahani A, Emami-Ardekani A, Fallahi B, Fard-Esfahani P, Beiki D, Hassanzadeh-Rad A, et al. Adverse effects of radioactive iodine-131 treatment for differentiated thyroid carcinoma. *Nucl Med Commun*. 2014;35(8):808–17.
6. Lee SL. Radioactive iodine therapy. *Curr Opin Endocrinol Diabetes Obes*. 2012;19(5):420–8.
7. Radioactive iodine therapy - statpearls - NCBI bookshelf [Internet]. [cited 2022Oct19]. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK557741/>
8. Lee Y, Chung CH, Lin LF, Chiu CH, Chen YF, Chang CF, et al. Radioactive Iodine Treatment for Thyroid Cancer Patients Increases the Risk of Long-Term Gastrointestinal Disorders: A Nationwide Population-Based Cohort Analysis. *Cancers (Basel)*. 2022;14(10).
9. Klein Hesselink EN, Links TP. Radioiodine Treatment and Thyroid Hormone Suppression Therapy for Differentiated Thyroid Carcinoma: Adverse Effects Support the Trend toward Less Aggressive Treatment for Low-Risk Patients. *Eur Thyroid J*. 2015;4(2):82–92.

10. Andresen NS, Buatti JM, Tewfik HH, Pagedar NA, Anderson CM, Watkins JM. Radioiodine Ablation following Thyroidectomy for Differentiated Thyroid Cancer: Literature Review of Utility, Dose, and Toxicity . *Eur Thyroid J.* 2017;6(4):187–96.
11. Onimode YA, Ejeh JE, Orunmuyi AT. Adverse Reactions to Radioiodine 131I Therapy of Goiter in West African Tertiary Hospital. *Molecular Imaging Radionucl Ther.* 2016;25(3):128–33.
12. efek samping. In: KBBI Daring. 2016.
13. Thyroid cancer - statpearls - NCBI bookshelf [Internet]. [cited 2022Nov6]. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK459299/>
14. Thyroid cancer - endotext - NCBI bookshelf [Internet]. [cited 2022Nov6]. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK285559/>
15. Jameson JL, Mandel SJ, Weetman AP. Thyroid Nodular Disease and Thyroid Cancer. In: Harrison's Principles of Internal Medicine. 20th ed. McGraw-Hill Education; 2018. p. 2714–8.
16. Li N, Du XL, Reitzel LR, Xu L, Sturgis EM. Impact of enhanced detection on the increase in thyroid cancer incidence in the United States: Review of incidence trends by socioeconomic status within the surveillance, epidemiology, and end results registry, 1980-2008. *Thyroid.* 2013;23(1):103–10.
17. Kumar V, Abbas AK, Aster JC, Turner JR, Perkins JA, Maitra A. The Endocrine System. In: Robbins & COTRAN pathologic basis of disease. Philadelphia, PA: Elsevier; 2021. p. 1086–92.
18. Penman ID, Ralston SH, J. SMW, Hobson RP, Davidson LS, Strachan MWJ, et al. Endocrinology. In: Davidson's principles and practice of medicine. 23rd ed. London ; New York ; Oxford ; Philadelphia ; St. Louis ; Sydney: Elsevier; 2018. p. 649–50.
19. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on

- Thyroid Nodules and Differentiated Thyroid Cancer. *Thyroid*. 2016;26(1):1–133.
20. Lee SL. Complications of radioactive iodine treatment of thyroid carcinoma. *JNCCN J Natl Compr Cancer Netw*. 2010;8(11):1277–87.
 21. Hyer SL, Newbold K, Harmer CL. Early and late toxicity of radioiodine therapy: Detection and management. *Endocr Pract*. 2010;16(6):1064–70.
 22. Van Nostrand D, Freitas JE, Sawka AM, Tsang RW. Side Effects of 131I for Therapy of Differentiated Thyroid Carcinoma. *Thyroid Cancer*. 2016. 671–708 p.
 23. Kita T, Yokoyama K, Higuchi T, Kinuya S, Taki J, Nakajima K, et al. Multifactorial analysis on the short-term side effects occurring within 96 hours after radioiodine-131 therapy for differentiated thyroid carcinoma. *Ann Nucl Med*. 2004;18(4):345–9.
 24. Lu L, Shan F, Li W, Lu H. Short-Term Side Effects after Radioiodine Treatment in Patients with Differentiated Thyroid Cancer. *Biomed Res Int*. 2016;2016:1–6.
 25. Article O. Pattern of short - term adverse effects in patients undergoing low - dose radioactive iodine therapy. 2022;67–73.
 26. Robeson WR, Ellwood JE, Margulies P, Margouleff D. Outcome and toxicity associated with maximum safe dose radioiodine treatment of metastatic thyroid cancer. *Clin Nucl Med*. 2002;27(8):556–66.
 27. Wierts R, Brans B, Havekes B, Kemerink GJ, Halders SG, Schaper NN, et al. Dose-response relationship in differentiated thyroid cancer patients undergoing radioiodine treatment assessed by means of 124I PET/CT. *J Nucl Med*. 2016;57(7):1027–32.
 28. Allahabadi A, Daykin J, Sheppard MC, Gough SCL, Franklyn JA. Radioiodine Treatment of Hyperthyroidism—Prognostic Factors for Outcome. *The Journal of Clinical Endocrinology & Metabolism*. 2001 Aug;86(8):3611–7.